Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL31P20 is a processed pseudogene resulting from retrotransposition of the functional RPL31 gene, which encodes a component of the 60S ribosomal subunit[7][2]. Like other ribosomal protein pseudogenes, RPL31P20 does not produce a functional protein, lacks intrinsic biological activity, and is not implicated directly in disease or drug targeting. Its presence in the genome primarily reflects the evolutionary history of ribosomal protein gene duplication and retrotransposition[2][6]. RPL31P20 is a pseudogene—by definition, it is not functionally expressed and does not encode a protein or active biomolecule[2][7]. It should not be considered a drug target, therapeutic target, or biomarker. No therapies, mechanisms of action, or biological functions are attributed to this entry. If you are seeking information on the therapeutic target, consider the parent gene “Ribosomal protein L31” (RPL31), but not the pseudogene RPL31P20.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L31 pseudogene 20 (RPL31P20).